Moreover, the activity of p53 can be regulated by various PTMs, including lactylation, acetylation, succinylation, UFMylation, and -hydroxybutyrylation
Notably, a recent STEP-HFpEF trial 105 reported that semaglutide significantly ameliorated heart failure-related symptoms in patients with obesity-related HFpEF and T2DM after one year of treatment
Contamination due to alternative weight loss intervention (Intervention and control) Since semaglutide was first licenced for the treatment of obesity in 2021, tirzepatide, a GLP-1/GIP receptor agonist with has even greater efficacy of weight loss, has achieved FDA approval in 2023
Even better, semaglutide stays active much longer than your natural GLP-1 hormone, creating stronger and longer-lasting appetite-control signals
Expect modest changes, not dramatic transformations